The Association Between Dietary Inflammatory Index and Parathyroid Hormone in Adults With/Without Chronic Kidney Disease

Aims: We aimed to assess the association between dietary inflammation index (DII) with parathyroid hormone (PTH) and hyperparathyroidism (HP) in adults with/without chronic kidney disease (CKD).Methods: Data were obtained from the 2003–2006 National Health and Nutrition Examination Survey (NHANES). The participants who were <18 years old, pregnant, or missing the data of DII, PTH, and CKD were excluded. DII was calculated based on a 24-h dietary recall interview for each participant. Weighted multivariable regression analysis and subgroup analysis were conducted to estimate the independent relationship between DII with PTH and the HP in the population with CKD/non-CKD.Results: A total of 7,679 participants were included with the median DII of −0.24 (−2.20 to 1.80) and a mean PTH level of 43.42 ± 23.21 pg/ml. The average PTH was 45.53 ± 26.63 pg/ml for the participants in the highest tertile group compared with 41.42 ± 19.74 pg/ml in the lowest tertile group (P < 0.0001). The rate of HP was 11.15% overall, while the rate in the highest DII tertile was 13.28 and 8.60% in the lowest DII tertile (P < 0.0001). The participants with CKD tended to have higher PTH levels compared with their counterparts (61.23 ± 45.62 vs. 41.80 ± 19.16 pg/ml, P < 0.0001). A positive association between DII scores and PTH was observed (β = 0.46, 95% CI: 0.25, 0.66, P ≤ 0.0001), and higher DII was associated with an increased risk of HP (OR = 1.05, 95% CI: 1.02, 1.08, P = 0.0023). The results from subgroup analysis indicated that this association was similar in the participants with different renal function, gender, age, BMI, hypertension, and diabetes statuses and could also be appropriate for the population with CKD.Conclusions: Higher consumption of a pro-inflammatory diet appeared to cause a higher PTH level and an increased risk of HP. Anti-inflammatory dietary management may be beneficial to reduce the risk of HP both in the population with and without CKD.

Download Full-text

History of kidney stones and risk of chronic kidney disease: a meta-analysis

PeerJ ◽

10.7717/peerj.2907 ◽

2017 ◽

Vol 5 ◽

pp. e2907 ◽

Cited By ~ 9

Author(s):

Weifeng Shang ◽

Lixi Li ◽

Yali Ren ◽

Qiangqiang Ge ◽

Ming Ku ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Kidney Stones ◽

Meta Analysis ◽

Positive Association ◽

Significant Heterogeneity ◽

Adjusted Risk ◽

Increased Risk ◽

Subgroup Analyses ◽

History Of

Background Although the relationship between a history of kidney stones and chronic kidney disease (CKD) has been explored in many studies, it is still far from being well understood. Thus, we conducted a meta-analysis of studies comparing rates of CKD in patients with a history of kidney stones. Methods PubMed, EMBASE, and the reference lists of relevant articles were searched to identify observational studies related to the topic. A random-effects model was used to combine the study-specific risk estimates. We explored the potential heterogeneity by subgroup analyses and meta-regression analyses. Results Seven studies were included in this meta-analysis. Pooled results suggested that a history of kidney stones was associated with an increased adjusted risk estimate for CKD [risk ratio (RR), 1.47 95% confidence interval (CI) [1.23–1.76])], with significant heterogeneity among these studies (I2 = 93.6%, P < 0.001). The observed positive association was observed in most of the subgroup analyses, whereas the association was not significant among studies from Asian countries, the mean age ≥50 years and male patients. Conclusion A history of kidney stones is associated with increased risk of CKD. Future investigations are encouraged to reveal the underlying mechanisms in the connection between kidney stones and CKD, which may point the way to more effective preventive and therapeutic measures.

Download Full-text

Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease

American Journal of Nephrology ◽

10.1159/000444423 ◽

2016 ◽

Vol 43 (1) ◽

pp. 20-31 ◽

Cited By ~ 3

Author(s):

Christopher L. Newman ◽

Nannan Tian ◽

Max A. Hammond ◽

Joseph M. Wallace ◽

Drew M. Brown ◽

...

Keyword(s):

Mechanical Properties ◽

Chronic Kidney Disease ◽

Parathyroid Hormone ◽

Kidney Disease ◽

Mineral Metabolism ◽

Standard Of Care ◽

Negative Effects ◽

Increased Risk ◽

The Impact ◽

Normal Controls

Background: Chronic kidney disease (CKD) leads to complex metabolic changes and an increased risk of fracture. Currently, calcitriol is the standard of care as it effectively suppresses parathyroid hormone (PTH) levels in CKD patients. While calcitriol and its analogs improve BMD and reduce fractures in the general population, the extension of these benefits to patients with advanced kidney disease is unclear. Here, the impact of calcitriol on the skeleton was examined in the setting of reduction in PTH. Methods: Male Cy/+ rats, a PKD-like CKD model, were treated with either vehicle or calcitriol for 5 weeks. Their normal littermates served as controls. Animals were assessed for changes in mineral metabolism and skeletal parameters (microCT, histology, whole bone mechanics and bone quality). Results: PTH levels were significantly higher (12-fold) in animals with CKD compared to normal controls. CKD animals also exhibited negative changes in bone structural and mechanical properties. Calcitriol treatment resulted in a 60% suppression of PTH levels in animals with CKD. Despite these changes, it had no impact on bone volume (cortical or cancellous), bone turnover, osteoclast number or whole bone mechanical properties. Conclusions: These data indicate that while calcitriol effectively lowered PTH in rats with CKD, it did little to prevent the negative effects of secondary hyperparathyroidism on the skeleton.

Download Full-text

Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis

Disease Markers ◽

10.1155/2021/8881393 ◽

2021 ◽

Vol 2021 ◽

pp. 1-11

Author(s):

Guangying Guo ◽

Aoran Huang ◽

Xin Huang ◽

Tianhua Xu ◽

Li Yao

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Sample Size ◽

Subgroup Analysis ◽

Meta Analysis ◽

Prognostic Role ◽

Increased Risk ◽

All Cause Mortality ◽

Cvd Mortality

Objective. Previous studies have controversial results about the prognostic role of soluble suppression of tumorigenicity 2 (sST2) in chronic kidney disease (CKD). Therefore, we conduct this meta-analysis to access the association between sST2 and all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events in patients with CKD. Methods. The publication studies on the association of sST2 with all-cause mortality, CVD mortality, and CVD events from PubMed and Embase were searched through August 2020. We pooled the hazard ratio (HR) comparing high versus low levels of sST2 and subgroup analysis based on treatment, continent, and diabetes mellitus (DM) proportion, and sample size was also performed. Results. There were 15 eligible studies with 11,063 CKD patients that were included in our meta-analysis. Elevated level of sST2 was associated with increased risk of all-cause mortality (HR 2.05; 95% confidence interval (CI), 1.51–2.78), CVD mortality (HR 1.68; 95% CI, 1.35–2.09), total CVD events (HR 1.88; 95% CI, 1.26–2.80), and HF (HR 1.35; 95% CI, 1.11–1.64). Subgroup analysis based on continent, DM percentage, and sample size showed that these factors did not influence the prognostic role of sST2 levels to all-cause mortality. Conclusions. Our results show that high levels of sST2 could predict the all-cause mortality, CVD mortality, and CVD events in CKD patients.

Download Full-text

Serum uric acid and risk of incident chronic kidney disease: a national cohort study and updated meta-analysis

Nutrition & Metabolism ◽

10.1186/s12986-021-00618-4 ◽

2021 ◽

Vol 18 (1) ◽

Author(s):

Nianwei Wu ◽

Jing Xia ◽

Sen Chen ◽

Chuan Yu ◽

Ying Xu ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Uric Acid ◽

Kidney Disease ◽

Cohort Studies ◽

Serum Uric Acid ◽

Meta Analysis ◽

Positive Association ◽

Effect Estimate ◽

Logistic Regression Models ◽

Increased Risk

Abstract Background We prospectively examined the association between serum uric acid (SUA) levels and chronic kidney disease (CKD) in China and updated the evidence through a comprehensive meta-analysis of prospective studies worldwide. Methods Our original analyses were based on data from the China Health and Retirement Longitudinal Study. The primary exposure of interest was SUA at baseline, and the main outcome was incident CKD. Logistic regression models were used to examine the association between SUA levels and incident CKD. A meta-analysis was performed to pool our effect estimate and those from other cohort studies. Results During a 4-year follow-up, 180 participants developed incident CKD. Participants in the highest SUA quartile were 2.73 times as likely to develop incident CKD compared to those in the lowest quartile (multivariable-adjusted OR, 2.73; 95% CI, 1.65–4.50). Each 1 mg/dL increment in the SUA levels was associated with a 49% increased risk of incident CKD (multivariable-adjusted OR, 1.49; 95% CI, 1.28–1.74). In the meta-analysis of 30 cohort studies (including the current study), pooled relative risks (95% CIs) of incident CKD were 1.15 (1.10–1.21) for SUA each 1 mg/dL increment, 1.22 (1.14–1.30) for the highest versus lowest SUA group, and 1.17 (1.12–1.23) for hyperuricemia versus no hyperuricemia. Conclusions Baseline SUA levels were associated with higher risk of incident CKD in middle-aged and elderly Chinese adults, and this positive association was confirmed in the meta-analysis of multiple cohort studies. Our findings may imply that SUA levels need to be routinely monitored for future CKD risk.

Download Full-text

Association of pesticides and kidney function among adults in the US population 2001-2010

10.21203/rs.3.rs-452983/v1 ◽

2021 ◽

Author(s):

En-Tzu Wan ◽

Darsy Darssan ◽

Shamshad Karatela ◽

Simon Reid ◽

Nicholas Osborne

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Kidney Function ◽

Dichlorophenoxyacetic Acid ◽

Cross Sectional ◽

Agricultural Communities ◽

Health And Nutrition ◽

Increased Risk ◽

Pesticide Exposures ◽

2,4 Dichlorophenoxyacetic Acid

Abstract Background Chronic kidney disease with unknown cause (CKDu) is prevalent in tropical and agricultural communities, however, its aetiology remains unclear. The objective of this study was to examine the association between pesticide exposures and the risk of kidney function loss using four waves of the National Health and Nutrition Examination Survey (NHANES) to identify a pathological pathway. Methods We pooled data from four cross-sectional waves of NHANES, providing 41,847 participants in total. Sub-population analyses for 2,4-dichlorophenoxyacetic acid (2,4-D), 3,5,6- trichloropyridinol, 3-phenoxybenzoic acid (3-PBA) and Malathion were conducted using. Logistic regression to estimate the odds ratios (ORs) and 95% CIs of the association between log-pesticide levels and kidney function. Results We found that Malathion acid increased the risk of low kidney function among the Malathion sub-population (aOR = 1.26, 95% CI = 1.01–1.56) in the adjusted model. Significantly increased risk of low kidney function was not found among the 2,4-D (aOR = 0.88, 95% CI = 0.72–1.09), 3,5,6-trichloropyridinol (aOR = 0.96, 95% CI = 0.83–1.12) and 3-PBA (aOR = 1.03, 95% CI = 0.94–1.13) subpopulations. Conclusions Our findings provide evidence of altered kidney function in people exposed to Malathion, highlighting the need to focus on Malathion acid as a potential cause of renal injury or chronic kidney disease.

Download Full-text

Association of mineral metabolism biomarkers with chronic kidney disease in Chinese adults

Clinical and Experimental Nephrology ◽

10.1007/s10157-021-02037-4 ◽

2021 ◽

Author(s):

Jialin Li ◽

Danni He ◽

Wenjing Zhao ◽

Xi’ai Wu ◽

Minjing Luo ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Parathyroid Hormone ◽

Kidney Disease ◽

Serum Calcium ◽

Mineral Metabolism ◽

Inorganic Phosphorus ◽

Intact Parathyroid Hormone ◽

Chinese Adults ◽

Increased Risk ◽

Advanced Stages

AbstractBackgroundWe aimed to examine the association of three mineral metabolism markers, including serum calcium, inorganic phosphorus, and intact parathyroid hormone with the risk of chronic kidney disease (CKD) at all stages.MethodsThis retrospective cohort study involved 3563 participants, including 3274 CKD patients and 289 healthy controls. CKD is diagnosed according to clinical guidelines from the 2012 KDIGO. Effect sizes are expressed odds ratio (OR) and 95 confidence interval (CI).ResultsAfter propensity score matching, per 0.5 mg/dL increment of inorganic phosphorus was significantly associated with 1.33-, 1.61-, and 2.85-fold increased risk of CKD at stages 1–2, 4, and 5, respectively. Regarding per 8 pg/mL increment of intact parathyroid hormone, significance was only noted for stage 5. In subsidiary analyses, the risk prediction of mineral metabolism markers under study was more evident in males and hypertensive subjects. A nomogram prediction model was constructed based on age, sex, and three mineral metabolism markers for CKD, with decent accuracy.ConclusionsOur findings indicate that serum calcium was associated with all-stage CKD risk, whereas the association for inorganic phosphorus and intact parathyroid hormone was significant at advanced stages.

Download Full-text

The Association between Parathyroid Hormone (PTH) Level and Hemoglobin and Hematocrit Level in Chronic Kidney Disease (CKD) Patients with Regular Hemodialysis

International Journal of Research and Review ◽

10.52403/ijrr.20211055 ◽

2021 ◽

Vol 8 (10) ◽

pp. 412-417

Author(s):

Hendri Wahyudi Pinem ◽

Alwi Thamrin Nasution ◽

Bayu Rusfandi Nasutio

Keyword(s):

Chronic Kidney Disease ◽

Parathyroid Hormone ◽

Kidney Disease ◽

Significant Relationship ◽

P Value ◽

Uremic Toxin ◽

Cross Sectional ◽

Minimum Value ◽

Pth Level ◽

Regular Hemodialysis

Introduction: Chronic Kidney Disease (CKD) is a pathophysiological process with various etiology that causes a progressive decline in kidney function and ends in kidney failure. [1] CKD is a health problem that occurs in the community and has covered globally. The 2010 Global Burden of Disease stated that CKD was the 27th leading cause of death in the world in 1990. This has increased to 18th in 2010. Parathyroid hormone is a potential factor in the incidence of anemia in CKD patients. In CKD patients, there is an increase in levels of parathyroid hormone which is a uremic toxin that inhibits erythropoietin by increasing fibrosis in the bone marrow (myelofibrosis). The role of PTH in cases of renal anemia has been extensively investigated by various clinical observational studies. This study aimed to determine the association between parathyroid hormone (PTH) levels and hemoglobin and hematocrit levels in chronic kidney disease (CKD) patients with regular hemodialysis in Haji Adam Malik Central General Hospital. Methods: This is an analytical study with a cross-sectional design. A total of 45 study subjects met the inclusion criteria and exclusion criteria, underwent history taking, physical examination, anthropometry, and laboratory examination to measure parathyroid hormone, hemoglobin, hematocrit, and albumin levels. Data analysis was performed using SPSS. Results: The measured PTH level had a minimum value of 113 pg/ml and a maximum of 595 pg/ml with an average of 431.4. The minimum hemoglobin value is 6.3 g/dl and a maximum of 11.5 g/dl with an average of 7.9, while for the hematocrit the minimum value is 19% and the maximum is 35% and the average is 24.7. The Mann-Whitney U test showed that there is a significant relationship between PTH levels and hemoglobin, indicated by a significant p value of 0.001 (p value < 0.05). A significant relationship was also found between PTH levels and hematocrit (p value = 0.039). Conclusion: Parathyroid hormone has a statistically significant relationship with haemoglobin and haematocrit levels in CKD patients with regular hemodialysis. Keywords: Chronic kidney disease; haemoglobin; haematocrit; parathyroid hormone; anemia; hemodialysis.

Download Full-text

Intact Parathyroid Hormone Level in Different Stages of Chronic Kidney Disease

Journal of Medical Science & Research ◽

10.47648/jmsr.2011.v1702.02 ◽

2011 ◽

Vol 17 (Number 2) ◽

pp. 9-14

Author(s):

N Y Mili ◽

R Begum ◽

Md. E Hoque ◽

Q S Akhter

Keyword(s):

Chronic Kidney Disease ◽

Parathyroid Hormone ◽

Kidney Disease ◽

Hormone Level ◽

Stage Iv ◽

Control Group ◽

Parathyroid Hormone Level ◽

Intact Pth ◽

Three Stages ◽

Pth Level

Secondary hyperparathyroidism is the first and most recognizable complication of chronic kidney disease (CKD) because parathyroid hormone (PTH) plays a compensatory role to maintain calcium and phosphate homeostasis. Progressive renal failure give rise to a steady increase in parathyroid hormone concentration. which is related to occurrence of renal bone disease. The objective of this study was to find out the httact parathyroid hormone level in different stages of chronic kidney disease patients. This cross sectional study was carried ow in the department of physiology. Dhaka Medical College from January to December 2009. 100 chronic kidney disease patients aged 20 to 60 years were selected as experimental group and 20 apparently healthy subjects were in control group and were matched for age and body weight. Patients were divided into three stages based on their creatinine clearance rate (Ccr). Group B, includes 34 patients marked as stage 11 with Ccr 60-89 ml/min, Group Ba Group B3 consists of 36 and 30 patients each and marked as stage 111 and stage IV with Ccr 30-59 mIhnin and 15-29 Skills respectively. Intact PTH was measured by chemiluminescent hnutuno assay method. Statistical analysis was done by unpaired Student's "1"- test and pearson's Correlation test. Mean serum PTH level was significantly higher in all experimental groups than that of control group (p< 0.001). High level of Pal was found in 74% patients in stage 11, 81% in stage III and 97% patients in stage IV. Again, a significant negative correlation of parathyroid hormone with Ccr was observed in patients with CKD in all three stages. From the findings of the present study it may be concluded that intact PTH level progressively increases from early stage to late stage of chronic kidney disease.

Download Full-text

Relationship between Plasma Leptin Level and Chronic Kidney Disease

International Journal of Nephrology ◽

10.1155/2012/269532 ◽

2012 ◽

Vol 2012 ◽

pp. 1-6 ◽

Cited By ~ 28

Author(s):

Anoop Shankar ◽

Shirmila Syamala ◽

Jie Xiao ◽

Paul Muntner

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Representative Sample ◽

Animal Studies ◽

Positive Association ◽

Hypertension Status ◽

Health And Nutrition ◽

Hemostatic Factors ◽

Race Ethnicity ◽

Plasma Leptin

Background. Leptin is an adipose tissue-derived hormone shown to be related to several metabolic, inflammatory, and hemostatic factors related to chronic kidney disease. Recent animal studies have reported that infusion of recombinant leptin into normal rats for 3 weeks fosters the development of glomerulosclerosis. However, few studies have examined the association between leptin and CKD in humans. Therefore, we examined the association between plasma leptin levels and CKD in a representative sample of US adults.Methods. We examined the third National Health and Nutrition Examination Survey participants >20 years of age (n=5820, 53.6% women). Plasma leptin levels were categorized into quartiles (≤4.3 Fg/L, 4.4–8.7 Fg/L, 8.8–16.9 Fg/L, >16.9 Fg/L). CKD was defined as a glomerular filtration rate of <60 mL/min/1.73 m2estimated from serum creatinine.Results. Higher plasma leptin levels were associated with CKD after adjusting for age, sex, race/ethnicity, education, smoking, alcohol intake, body mass index (BMI), diabetes, hypertension, and serum cholesterol. Compared to quartile 1 of leptin (referent), the odds ratio (95% confidence interval) of CKD associated with quartile 4 was 3.31 (1.41 to 7.78);P-trend= 0.0135. Subgroup analyses examining the relation between leptin and CKD by gender, BMI categories, diabetes, and hypertension status also showed a consistent positive association.Conclusion. Higher plasma leptin levels are associated with CKD in a representative sample of US adults.

Download Full-text

Abstract P551: Impact of Chronic Kidney Disease on Stroke Outcomes After Endovascular Thrombectomy - A Matched Cohort Study

Stroke ◽

10.1161/str.52.suppl_1.p551 ◽

2021 ◽

Vol 52 (Suppl_1) ◽

Author(s):

Aaron Ravelo ◽

Chris Hackett ◽

Russell Cerejo ◽

David G Wright ◽

Richard Williamson ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Propensity Score ◽

Propensity Score Matching ◽

Subgroup Analysis ◽

Inpatient Mortality ◽

Stroke Outcomes ◽

Discharge Disposition ◽

Increased Risk ◽

Length Of Hospitalization

Objective: To determine the impact of chronic kidney disease (CKD) on stroke outcomes stratified by severity of renal impairment among acute ischemic strokes (AIS) patients treated with endovascular therapy (EVT). Methods: Single center retrospective analysis was conducted from January 2012 to December 2019 involving AIS patients with CKD undergoing EVT. We evaluated following primary safety and efficacy outcomes: inpatient mortality and reperfusion status according to TICI score, respectively. Our secondary safety outcomes were symptomatic intracranial hemorrhage (sICH) per SITS-MOST definition, whereas secondary efficacy outcomes were length of hospitalization and favorable discharge disposition (discharge to home or inpatient rehabilitation). CKD was defined with estimated glomerular filtration rate (eGFR) ranging from mild (eGFR 60-89 mL/ min) to moderate (eGFR 30-59 mL/min) to severe (eGFR 15-29 mL/min). We performed propensity score matching to eliminate confounding variables between CKD and non-CKD patients (1:2). In our subgroup analysis, we compared patients with mild-moderate CKD patients and severe CKD and evaluated their association with various clinical outcomes. Results: From a total of 466 AIS patients undergoing EVT, 84 CKD and 165 patients with normal renal function were selected based on 1:2 propensity score matching. CKD was associated with increased risk of in-hospital mortality (Odds ratio [OR] 2.58, 95% confidence interval [CI] 1.49-4.64, p <0.001), whereas favorable discharge disposition, length of hospitalization, sICH, TICI 2B/3 were comparable between the two groups. Subgroup analysis showed that patients with mild and moderate CKD were observed to have favorable discharge disposition (p=0.002), whereas patients with severe CKD were noted to have a higher risk of sICH ( p = 0.03) and prolonged hospitalization 11.54 ± 11.87 days (OR; 1.10, 95% CI 1.03-1.18, p = 0.006). Conclusion: History of CKD among AIS patients undergoing EVT were associated with a higher rate of inpatient mortality. In comparison to patients with mild and moderate CKD, patients with severe CKD were noted to have an increased risk of sICH, prolonged hospitalization, and poor discharge disposition.

Download Full-text